Panacea Biotec Intrinsic Value
Panacea Biotec intrinsic value. Panacea Biotec (PANACEABIO) median intrinsic value is ₹705.70 from 8 valuation models (range ₹106–₹882), vs current price ₹352.85 — +100.0% upside (Trading Below Calculated Value), margin of safety 50.0%. Analyse PANACEABIO FII DII holdings to track promoter, FII and institutional holdings.
PANACEABIO Valuation Methods Summary — DCF, Graham Number & P/E
Panacea Biotec intrinsic value across 8 models vs current price ₹352.85 — upside/downside and value range per method. Browse PANACEABIO financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹167.20 | ₹133.76 - ₹200.64 | -52.6% | EPS: ₹7.60, Sector P/E: 22x |
| Book Value Method | asset | ₹882.12 | ₹793.91 - ₹970.33 | +150.0% | Book Value/Share: ₹1381.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹705.70 | ₹635.13 - ₹776.27 | +100.0% | Revenue/Share: ₹1326.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹705.70 | ₹635.13 - ₹776.27 | +100.0% | EBITDA: ₹100.00Cr, EV/EBITDA: 10x |
| PEG Ratio Method | growth | ₹105.86 | ₹95.27 - ₹116.45 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹117.42 | ₹105.68 - ₹129.16 | -66.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹705.70 | ₹635.13 - ₹776.27 | +100.0% | ROE: 5.8%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹486.07 | ₹437.46 - ₹534.68 | +37.8% | EPS: ₹7.60, BVPS: ₹1381.67 |
PANACEABIO Intrinsic Value vs Market Price — All Valuation Models
Panacea Biotec fair value range ₹106–₹882 vs current market price ₹352.85 across 8 valuation models. For current market price and key ratios, visit Panacea Biotec share price screener.
PANACEABIO Intrinsic Value Analysis — Undervalued or Overvalued?
Panacea Biotec median intrinsic value ₹705.70, current price ₹352.85 — Trading Below Calculated Value by 100.0%, margin of safety 50.0%.
What is the intrinsic value of PANACEABIO?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of Panacea Biotec (PANACEABIO) is ₹705.70 (median value). With the current market price of ₹352.85, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹105.86 to ₹882.12, indicating ₹105.86 - ₹882.12.
Is PANACEABIO undervalued or overvalued?
Based on our multi-method analysis, Panacea Biotec (PANACEABIO) appears to be trading below calculated value by approximately 100.0%.
PANACEABIO Financial Health — Key Ratios vs Industry Benchmarks
Panacea Biotec financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 5.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 8.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.63x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
PANACEABIO Cash Flow Quality — Operating & Free Cash Flow
Panacea Biotec operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹17 Cr | ₹-4 Cr | Positive Operating Cash Flow | 6/10 |
| March 2025 | ₹-27 Cr | ₹-27 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-423 Cr | ₹-423 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-108 Cr | ₹-108 Cr | Negative Cash Flow | 3/10 |